Sphingosine kinase regulation and cardioprotection

Cardiovascular Research

Volumn 82, Issue 2, 2009, Pages 184-192

  Karliner, Joel S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardioprotection; Enzyme regulation; Ischaemia reperfusion injury; Ischaemic postconditioning; Ischaemic preconditioning; Sphingosine kinase; Sphingosine 1 phosphate

Indexed keywords

GANGLIOSIDE GM1; SPHINGOSINE; SPHINGOSINE KINASE; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2;

CELL CULTURE; ENZYME ACTIVITY; ENZYME REGULATION; GENE TARGETING; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPOXIA; INCUBATION TIME; ISCHEMIC PRECONDITIONING; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LYSOPHOSPHOLIPIDS; MICE; MYOCARDIAL REPERFUSION INJURY; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RATS; SPHINGOSINE;

EID: 67449128428     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn309     Document Type: Review

References (104)

1. Cuvillier O, Pirianov G, Keluser B, Vanek PG, Coso A, Gutkind S et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381:800 803.
2. Allende ML, Praia RL. Sphingosine-1-phosphate receptors and the development of the vascular system. Biochim Biophys Acta 2002; 1582:222-227.
3. Wendler CC, Rivkees SA. Sphingosine-1-phosphate inhibits cell migration and endothelial to mesenchymal cell transformation during cardiac development. Develop Biol 2006;291:264-277.
4. Yatomi Y. Sphingosine 1-phosphate in vascular biology: possible therapeutic strategies to control vascular diseases. Curr Pharm Des 2006;12:575-587.
5. Yan G, Chen S, You B, Sun J. Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids. Cardiovasc Res 2008;78:308-314.
6. Schwalm S, Doll F, Romer I, Bubovna S, Pfeilschifter J, Huwiler A. Sphingosine kinase-1 is a hypoxia-regulated gene that stimulates migration of human endothelial cells. Biochem Biophys Res Commun 2008;368:1020- 1025.
7. Li X, Stankovic M, Bonder CS, Hahn CN, Parsons M, Pitson SM et al. Basal and angiopoietin-1 -mediated endothelial permeability is regulated by sphingosine kinase-1. Blood 2008;111:3489-3497.
8. 2+ metabolism. J Pharmacol Exp Ther 2007;323:186-191.
9. Venkataraman K, Lee Y-M, Michaud J, Thangada S, Ai Y, Bonkovsky HL et al. Vascular endothelium as a contributor of plasma sphingosine 1phosphate. Circ Res 2008;102:669-676.
10. Igarashi J, Michel T. The enigma of sphingosine 1-phosphate synthesis. A novel role for endothelial sphingosine kinases. Circ Res 2008; 102: 630-632.
11. Peters SLM, Alewijnse AE. Sphingosine-1-phosphate signaling in the cardiovascular system. Curr Opin Pharmacol 2007;7:186-192.
12. Alemany R, van Koppen CJ, Dannebeg K, ter Braak M, Meyer zu Heringdorf D. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol 2007;374:413-428.
13. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature Reviews. Mol Cell Biol 2008;9:139-150.
14. Alewijnse AE, Peters SLM. Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur J Pharmacol 2008;585:292-302.
15. Olivera A, Kohama T, Tu Z, Milstien S, Spiegel S. Purification and characterization of rat kidney sphingosine kinase. J Biol Chem 1998;273: 12576-125783.
16. Kohama T, Olivera A, Edsalll L, Nagiec MM, Dickson R, Spiegel S. Molecular cloning and functional characterization of murine sphingosine kinase. J Biol Chem 1998;273:23722-23728.
17. Melendez AH, Carlos-Dias E, Gosink M, Allen JM, Takacs L. Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution. Gene 2000;251:19-26.
18. Nava VE, Lacana E, Poulton S, Liu H, Sugiura M, Kono K et al. Functional characterization of human sphingosine kinase-1. FESS Lett 2000;473: 81-84.
19. Pitson SM, Moretti PAB, Zebol JR, Zareie R, Derian CK, Darrow AL et al. The nucleotide-binding site of human sphingosine kinase 1. J Biol Chem 2002;277:49545-49553.
20. Sutherland CM, Moretti PAB, Hewitt NM, Bagley CJ, Vadas MA, Pitson SM. The calmodulin-binding site of sphingosine kinase and its role in agonistdependent translocation of sphingosine kinase 1 to plasma membrane. J Biol Chem 2006;281:11693-11701.
21. Park CG, Lee HS, Lee HY, Park CS, Choi OH. Cloning and characterization of rat sphingosine kinase 1 with an N-terminal extension. Biochem Biophys Res Commun 2007;364:702-707.
22. Liu H, Sugiura M, Nava VE, Edsall LC, Kono K, Poulton S et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 2000;275:19513- 19520.
23. Imamura T, Ohgane J, lto S, Ogawa T, Hattori N, Tanaka S et al. CpG island of rat sphingosine kinase-1 gene: tissue-dependent DNA methylation status and multiple alternative first exons. Genomics 2001 ;76: 117-125.
24. Okada T, Ding G, Sonoda H, Kajimoto T, Hga Y, Khosrowbeygi A et al. Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. J Biol Chem 2005;280:36318-36325.
25. Liu H, Sugiura M, Nava VE, Edsal LC, Kono K, Poulton S et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J Biol Chem 2000;275:19513- 19520.
26. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Praia RL. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005;25:11113-11121.
27. Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, Echten-Deckert G et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 2004; 279:52487-52492.
28. Michaud J, Kohno M, Proia RL, HIa T. Normal acute and chronic inflammatory responses in sphingosine kinase 1 knockout mice. FESS Lett 2006;580:4607-4612.
29. 2 signaling. FESS Lett 2007;58:4384-4388.
30. Meacci E, Nuti F, Donati C, Cencetti F, Farnararo M, Bruni P. Sphingosine kinase activity is required for myogenic differentiation of C2C12 myoblasts. J Cell Physiol 2008;214:210-220.
31. Cavallini L, Venerando R, Miotto G, Alexandre A. Ganglioside GM1 protection from apoptosis of rat heart fibroblasts. Arch Biochem Biophys 1999;370:156-162.
32. Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, Vadas MA et al. Activation of sphingosine kinase 1 by ERK 1/2-mediated phosphorylation. EMBO J 2003;22:5491-5500.
33. Xia P, Wang L, Moretti PA, Albanese N, Chai F, Pitson SM et al. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor alpha signaling. J Biol Chem 2002;277:7996-8003.
34. Pitson SM, Moretti PA, Zebol JR, Xia P, Gamble JR, Vadas MA et al. Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase. J Biol Chem 2000;275:33945-33950.
35. Fujita T, Okada T, Hayshi S, Hahangeer S, Miwa N, Nakamura S. Delta-catenin/NRRAP (neural plakophilin-related armadillo repeat protein) interacts with and activates sphingosine kinase 1. Biochem J 2004; 382:717-723.
36. Maceyka M, Payne SG, Milstien S, Spiegel S. Aminocyclase 1 is a sphingosine kinase 1-interacting protein. FEBS Lett 2004;568:30- 34.
37. Leclercq TM, Moretti PA, Vadas MA, Pitson SM. Eukaryotic elongation factor 1 interacts with sphingosine kinase and directly enhances its catalytic activity. J Biol Chem 2008;283:9606-9614.
38. Lacana E, Maceyka M, Milstien S, Spiegel S. Cloning and characterization of a protein kinase A anchoring protein (AKAP)-related protein that interacts with and regulates sphingosine kinase 1 activity. J Biol Chem 2002;277:32947-32953.
39. Fukuda Y, Aoyama Y, Wada A, lgarashi Y. Identification of PECAM-1 association with sphingosine kinase 1 and its regulation by agonist-induced phosphorylation. Biochim Biophys Acta 2004; 1636: 12-21.
40. Sun J, Yan G, Ren A, You B, Liao JK. FHL2/SLIM3 decreases cardiomyocyte survival by inhibitory interaction with sphingosine kinase-1. Circ Res 2006;99:468-476.
41. Hayashi S, Okada T, lgararshi N, Fujita T, Jahangeer S, Nakamura S. Identification and characterization of RPK118, a novel sphingosine kinase-1-binding protein. J Biol Chem 2002;277:33319-33324.
42. 2+ signals triggered by different phospholipid pathways in antigen stimulation of human mast cells. J Biol Chem 2002;277:17255-17262.
43. Meyer zu Heringdorf D. Lysophospholipid receptor-dependent and independent calcium signaling. J Cell Biochem 2004;92:937-948.
44. Venkataraman K, Thangada S, Michaud J, Oo ML, Ai Y, Lee YM et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J 2006;397:461-471.
45. Mitra P, Oskeritian CA, Payne SG, Beaven MA, Mistien S, Spiegel S. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA 2006;103:16394-16399.
46. Pchejetski D, Kunduzova O, Dayhon A, Calise D, Suguelas M-H, Leducq N et al. Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 2007;100:41-49.
47. Anelli V, Gault CR, Cheng AB, Obeid LM. Sphingosine kinase 1 is up-regulated during hypoxia in U87MG glioma cells. Role of hypoxia-inducible factors 1 and 2. J Biol Chem 2008;283:3365-3375.
48. Vessey DA, Kelley M, Zhang J, Li L, Tao R, Karliner JS. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J Biochem Mol Toxicol 2007;21:273-279.
49. Taha TA, Kitatani K, El-Alwani M, Bielawski J, Hannun YA et al. Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. FASEB J 2006;20:482-484.
50. Ikeda Y, Ohashi K, Shibata R, Pimentel DR, Kihara S, Ouchi N et al. Cycloosygenase-2 induction by adiponectin is regulated by a sphingosine kinase-1 dependent mechanism in cardiac myocytes. FESS Lett 2008; 582:1147-1150.
51. Kacimi R, Vessey DA, Honbo N, Karliner JS. Adult cardiac fibroblasts null for sphingosine kinase-1 exhibit growth dysregulation and an enhanced proinflammatory response. J Mol Cell Cardiol 2007;43:85-91.
52. Cuvillier O, Levade T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/ DIABLO from mitochondria. Blood 2001;98:2828-2836.
53. Dindo D, Dahm F, Szulc Z, Bielawska A, Obeid LM, Hannun YA et al. Cationic long-chain ceramide LCL-30 induces cell death by mitochondrial targeting in SW403 cells. Mol Cancer Ther 2006;5:1520-1529.
54. Gustafsson AB, Gottlieb RA. Recycle or die: the role of autophagy in cardioprotection. J Mol Cell Cardiol 2008;44:654-661.
55. Lavieu G, Scarlatti F, Sala G, Carpentier S, Levade T, Ghidoni R et al. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J Biol Chem 2006;281:8518- 8527.
56. Lavieu G, Scarlatti F, Sala G, Levade T, Bhidoni R, Botti J et al. Is autophagy the key mechanism by which the sphingolipid rheostat controls the cell fate decision? Autophagy 2007;3:45-47.
57. Takabe K, Paugh SW, Milstien S, Spiegel S. 'Inside-Out' signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008; 60:181-195.
58. Tao R, Zhang J, Vessey DA, Honbo N, Karliner JS. Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res 2007;74:56-63.
59. Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu JD, Griffiths R et al. Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a 'come-and-get-me' signal. FASEB J 2008; 22:2629-2638.
60. Okada T, Ding G, Sonoda H, Kajimoto T, Haga Y, Khosrowbeygi A et al. Involvement of N-terminal-extended form of sphingosine kinase 2 in serum-dependent regulation of cell proliferation and apoptosis. J Biol Chem 2005;280:36318-36325.
61. Hait NC, Bellamy A, Milstien S, Kordula T, Spiegel S. Sphingosine kinase type 2 actiation by ERK-mediated phosphorylation. J Biol Chem 2007; 282:12058-12065.
62. Maceyka M, Sankkala H, Hait NC, Le Stunff H, Liu H, Toman R et al. SphK1 and Sphk2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 2005;280:37118-37129.
63. Spiegel S, Milstien S. Functions of the multifaceted family of sphingosine kinases and some close relatives. J Biol Chem 2007;282:2125-2129.
64. Le Stunff H, Giussani P, Maceyka M, Lepine S, Milstien S, Spiegel S. Recycling of sphingosine is regulated by the concerted actions of sphingosine-1-phosphate phosphohydrolase 1 and sphingosine kinase 2. J Biol Chem 2007;282:34372-34380.
65. Okada T, Ding G, Sonoda H, Kajimoto T, Haga Y, Khosrowbeygi A et al. Involvement of N-terminal extended form of sphingosine kinase-2 in serum dependent cell proliferation and apoptosis. J Biol Chem 2005; 280:36318-36325.
66. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer, Nakamura S. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 2003;278:46832-46839.
67. Liu H, Toman RE, Goparaju SK, Maceyka M, Nava VE, Sankala H et al. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem 2003;278:40330-40336.
68. Ding G, Sonoda H, Yu H, Kajimoto T, Goparaju SK, Hahangeer S et al. Protein kinase D-mediated phosphorylation and nuclear export of sphingosine kinase 2. J Biol Chem 2007;282:27493-27502.
69. Merrill AH Jr, Schmelz EM, Dillehay DL, Spiegel S, Shayman JA, Schroeder JJ et al. Sphingolipids-the enigmatic lipid class: biochemistry, physiology and pathophysiology. Toxicol Appl Pharmacol 1997;142: 208-225.
70. Billich A, Bornacin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 2003;278:47408-47415.
71. Sanchez T, Estrada-Hernandez T, Paik J-H, Wu M-T, Venkataraman K, Brinkmann V et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2002;278:47281-47290.
72. Kharel Y, Lee S, Snyder AH, Sheasley-O'Neill S, Morris MA, Setiady Y et al. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J Biol Chem 2005;280:36865-36872.
73. Zemann B, Kinzel B, Muller M, Reuschel R, Mechtcheriakova D, Urtz N et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Siood 2006; 107:1454-1458.
74. Hogenauer K, Billich A, Pally C, Streiff M, Wagner T, Welzenbach K et al. Phosphorylation by sphingosine kinase 2 is essential for in vivo potency of FTY720 analogues. ChemMedChem 2008;3:1027-1029.
75. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007;115:84-105.
76. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-1140.
77. Karliner JS, Honbo N, Summers K, Gray MO, Goetzl EJ. The lysophospholipids sphingosine-1-posphate and lysophosphatidic acid enhance survival during hypoxia in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2001;33:1713-1717.
78. Zhang J, Honbo N, Goetzl EJ, ChatterjeeK, Karliner JS, Gray MO. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol 2007;293:H3150-H3158.
79. Sonin D, Zhou SY, Cronin C, Sonina T, Wu J, Jacobson KA et al. Role of P2X purinergic receptors in the rescue of ischemic heart failure. Am J Physiol Heart Circ Physiol 2008;295:H1191-H1197.
80. Jin ZQ, Zhou HZ, Zhu P, Honbo N, Mochly-Rosen D, Messing RO et al. Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol 2002;282:H1970-H1977.
81. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNFα and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002; 34:509-518.
82. Gray MO, Zhou HZ, Schafhalter-Zoppoth I, Zhu P, Mochly-Rosen D, Messing RO. Preservation of base-line hemodynamic function and loss of inducible cardioprotection in adult mice lacking protein kinase C epsilon. JBiol Chem 2004;279:3596-3604.
83. Jin Z-Q, Goetzl EJ, Karliner JS. Sphingosine kinase activation mediates ischemic preconditioning in murine heart. Circulation 2004; 110: 1980-1989.
84. Jin Z-Q, Karliner JS. Low dose N, N-dimethylsphingosine is cardioprotective and activates cytosolic sphingosine kinase by a PKCe dependent mechanism. Cardiovasc Res 2006;71:725-734.
85. 2+ channel conductance. Circ Res 1994;75:981-989.
86. Suzuki E, Handa K, Toledo Ms, Hakomori S. Sphingosine-dependent apoptosis: A unified concept based on multiple mechanisms operating in concert. Proc Natl Acad Sd USA 2004;101:14788-14793.
87. Vessey DA, Li L, Kelley M, Zhang J, Karliner JS. Sphingosine can pre-and post-condition heart and utilizes a different mechanism from sphingosine 1-phosphate. J Biochem Mol Toxicol 2008;22:113-118.
88. Vessey DA, Kelley M, Karliner JS. A rapid radioassay for sphingosine kinase. Anal Biochem 2005;337:136-142.
89. Vessey DA, Kelley M, Li L, Huang Y, Zhou H-Z, Zhu BQ et al. Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit 2006;12:318-324.
90. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316:295-298.
91. Jin Z-Q, Zhang J, Huang Y, Hoover HE, Vessey DA, Karliner JS. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/ reperfusion injury. Cardiovasc Res 2007;76:41-50.
92. Nishino Y, Webb I, Marber MS. Editorial. Sphingosine kinase isoforms and cardiac protection. Cardiovasc Res 2007;76:3-4.
93. Duan H-F, Wang H, Yi J, Liu H-J, Zhang Q-W, Li L-G et al. Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/ reperfusion-induced injury and attenuates its postischemic failure. Hum Gene Ther 2007;18:1119-1128.
94. Kim M, Kim M, Kim N, D'Agati VD, Emala CW Sr, Lee HT lsoflurane mediates protection from renal ischemia-reperfusion injury via sphingosine kinase and sphingosine-1-phosphate-dependent pathways. Am J Physiol Renal Physiol 2007;293:F1827-F1835.
95. Sankala HM, Hait NC, Paugh SW, Shida D, Lepine S, Elmore LW et al. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 2007;67: 10466-10474.
96. Sobue S, Nemoto S, Murakami M, lto H, Kimura A, Gao S et al. Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells, Int J Hematol 2008;87:266-275.
97. Ma MM, Chen JL, Wang GG, Wang H, Lu Y, Li JF et al. Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia 2007;50:891-900.
98. Zhao ZQ, Corvera JS, Jalos ME, Kerendi F, Wang NP, Guyton RA et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-H588.
99. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G et al. Long-term benefit of postconditioning. Circulation 2008; 117: 1037-1044.
100. Jin Z-Q, Karliner JS, Vessey DA. Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res 2008;79:134-140.
101. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008;88:581-609.
102. Tritto I, D'Andrea D, Eramo N, Scognamiglio A, De Simone C, Violante A et al. Oxygen radicals can induce preconditioning in rabbit hearts. Circ Res 1997;80:743-748.
103. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activation prosurvial kinases at reperfusion. Am J Physiol Heart Circ Physiol 2005;288:H971-H976.
104. Vessey DA, Li L, Kelley M, Karliner JS. Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. Biochem Biophys Res Commun 2008;375:425-429.